Los puntos clave no están disponibles para este artículo en este momento.
The principles of molecular property optimization in drug design have been understood for decades, yet much drug discovery activity today is conducted at the periphery of historical druglike property space. Lead optimization trajectories aimed at reducing physicochemical risk, assisted by ligand efficiency metrics, could help to reduce clinical attrition rates.
Leeson et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: